Cite

HARVARD Citation

    Yang, H. et al. (2017). Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer. Scientific reports. 7 (1), pp. 1-8. [Online]. 
  
Back to record